Meropenem Dosing in Dialysis Patients
For patients on intermittent hemodialysis, administer meropenem at half the recommended dose (250 mg for skin/soft tissue infections or 500 mg for intra-abdominal infections) every 24 hours, given after each dialysis session. This recommendation is based on the FDA-approved dosing for severe renal impairment 1.
Dosing by Dialysis Modality
Intermittent Hemodialysis (IHD)
The FDA label provides clear guidance for patients with creatinine clearance <10 mL/min 1:
- Complicated skin/soft tissue infections: 250 mg every 24 hours
- Intra-abdominal infections: 500 mg every 24 hours
- Timing: Administer doses immediately after dialysis sessions to avoid premature drug removal
Critical caveat: The FDA label explicitly states "there is inadequate information regarding the use of meropenem in patients on hemodialysis" 1, yet provides these dosing recommendations based on pharmacokinetic principles.
Continuous Renal Replacement Therapy (CRRT)
For critically ill patients receiving CRRT, the optimal regimen is 750 mg every 8 hours regardless of whether they're receiving continuous venovenous hemofiltration (CVVH) or continuous venovenous hemodialysis (CVVHD) 2, 3. This applies to both standard (20-25 mL/kg/h) and high (35 mL/kg/h) effluent rates.
Recent population pharmacokinetic studies support 500 mg every 8 hours or 1 gram every 12 hours for patients with acute kidney injury on continuous hemodiafiltration (CHDF), targeting bacteria with MIC ≤2 mg/L 4.
Prolonged Intermittent Renal Replacement Therapy (PIRRT)
For PIRRT, dosing depends on session frequency and duration 5:
Alternate-day PIRRT:
- Most session durations: 1000 mg loading dose, then 500 mg every 8 hours
- 10-hour hemodialysis sessions: 1000 mg every 12 hours
Daily PIRRT:
- Hemodialysis (4-8 hour sessions): 750 mg every 8 hours
- Hemodialysis (10-hour sessions): 1000 mg every 8 hours
- Hemofiltration varies by duration: 500 mg every 8 hours (4-hour) to 750 mg every 8 hours (10-hour)
Peritoneal Dialysis
For automated peritoneal dialysis (APD), intraperitoneal administration of 750 mg daily is optimal for pathogens with MIC 2-8 mg/L 6. This dosing achieves adequate concentrations in both plasma and dialysate without significant drug accumulation.
The FDA label notes "data currently are not available for patients receiving peritoneal dialysis" 1, but tuberculosis guidelines suggest starting with hemodialysis doses and verifying adequacy through therapeutic drug monitoring 7.
Key Clinical Considerations
Pharmacodynamic targets: Meropenem requires free drug concentrations above the MIC for 40% of the dosing interval (40% fT>MIC) for bacteriostatic effect, and ideally 100% fT>MIC for optimal bactericidal activity 2, 4.
Timing with dialysis: Always administer meropenem immediately after hemodialysis sessions to prevent premature drug removal and facilitate directly observed therapy 7.
Therapeutic drug monitoring: Given the significant pharmacokinetic variability in dialysis patients, therapeutic drug monitoring is strongly encouraged when available, particularly for:
- Patients with residual renal function
- Those receiving CRRT or PIRRT
- Infections with organisms having higher MICs (4-8 mg/L)
- Critically ill patients with altered volumes of distribution 8, 4
Residual renal function: Patients with residual creatinine clearance >50 mL/min receiving CRRT may have significantly increased meropenem clearance (up to fivefold), potentially requiring dose adjustments 8.
Common pitfall: Do not use standard dosing in dialysis patients—meropenem is significantly removed by dialysis and accumulates in renal failure, risking both treatment failure (underdosing) and neurotoxicity including seizures (overdosing) 1.